Comparative in vitro Activity and Clinical Outcomes of Eravacycline, Tigecycline, and Omadacycline Against Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae Corrigendum | Synapse
March 24, 2026Open Access
Comparative in vitro Activity and Clinical Outcomes of Eravacycline, Tigecycline, and Omadacycline Against Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae Corrigendum
Key Points
To correct information regarding the in vitro effectiveness of eravacycline, tigecycline, and omadacycline against specific resistant bacteria.
Corrected clinical outcomes from previous analyses.
Re-evaluated in vitro activity against Acinetobacter baumannii and Klebsiella pneumoniae.
Clarifications provided on the efficacy of the three antibiotics.
Revisions made to improve accuracy of clinical outcome assessments.
Abstract
Corrigendum for the article Comparative in vitro Activity and Clinical Outcomes of Eravacycline, Tigecycline, and Omadacycline Against Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae